Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT05637268
Phase
PHASE2
Status
Unknown

Conditions

  • Esophagus Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg iv q2w
  • Paclitaxel — DRUG
    150mg/m² iv d1 q2w
  • Cisplatin — DRUG
    50 mg/m² iv d2 q2w

Study Details

This is a single-arm, open, exploratory clinical study to evaluate the efficacy and safety of camrelizumab combined with chemotherapy for adjuvant treatment of nodal positive thoracic esophageal squamous cell carcinoma.

Key Dates

Start date
Nov 26, 2020
Status verified
Nov 2022
Primary completion
Jun 1, 2024
Completion
Jun 1, 2025

Study Design

Enrollment
23 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    Treatment with camrelizumab combined with chemotherapy was planned for 4 to 6 cycles, after which carrilizumab monotherapy was maintained until disease progression, unacceptable toxicity, or patient withdrawal. A total of 4 to 6 cycles, after carrilizumab maintenance treatment for one year.

Primary Outcome Measure

3-year DFS rate [ Time Frame: 8 weeks ]

Central Contacts

Related Studies